All News
Pregnancy Outcomes with Belimumab
Pregnancy in systemic lupus erythematosus (SLE) is fraught with problems of adverse pregnancy outcomes, more pregnancy loss and birth defects. Now a study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects.
Read Article
Prevotella Immune Response in Both Pre-Clinical & Established RA
In a recent analysis published in Arthritis & Rheumatology, people at risk for rheumatoid arthritis (RA) and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc).
Read Article
Miners Face Increased Risk of Rheumatoid Arthritis
Add "hard rock" mining to the list of occupations associated with high rates of rheumatoid arthritis (RA), a new study indicated, with silica exposure the presumed malefactor.
Read Article
CRTAC1- a Novel Biomarker for Osteoarthritis
Scientists at deCODE genetics a subsidiary of Amgen report in Arthritis & Rheumatology that a novel plasma protein (cartilage acidic protein-1; CRTAC1) is a potential biomarker of osteoarthritis (OA) through its association with OA risk and progression to joint replacement.
Read Article
Links:
Links:
Predicting Cardiovascular Events in SLE
A study from the Georgia Lupus Registry shows that systemic lupus erythematosus patients are at greatest risk for cardiovascular disease events between years 2 and 11 after diagnosis and higher in Black people or those with a discoid rash.
Read Article
Second Efforts in Treating RA Partial Responders
The results of a treat-to-target (T2T) combination therapy trial in patients with early rheumatoid arthritis (RA) show that if patients fail to respond initially, then a second, more intensified regimen can turn initial nonresponders into responders.
Read Article
Good Outcomes with TNF Blocker Use During RA Pregnancies
A prospective cohort study of treatment and pregnancy outcomes in women with RA shows that TNF inhibitor use during pregnancy did not increase the risk of adverse pregnancy outcomes, but instead led to more positive outcomes such as fewer low-birth-weight deliveries.
Read Article
Intravenous Immune Globulin in Dermatomyositis
Few drugs have been studied well in the treatment of dermatomyositis (DM) and only recently has intravenous immune globulin (IVIG) been granted FDA approval for the treatment of DM, based on this pivotal trial.
Read Article
Links:
Links:
Tofacitinib shows promise in scleroderma
Systemic sclerosis is one of the rarest autoimmune diseases, affecting roughly 100,000 people (primarily women) in the U.S. With no licensed treatments available for this subset of scleroderma patients, rheumatology researchers are searching for opportunities to use resources and technology that have proven beneficial in treating other autoimmune and rheumatic diseases.
Read Article
RheumNow Podcast – “That’s Not My Name” (10.7.2022)
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.
Read Article
Women Doctors More Likely to Be Called By First Name in Patient Messages
Female physicians were more likely to be called by their first names in electronic medical record (EMR) patient portal messaging, researchers found.
Read Article
Orthopedic surgery patients do fine without opioid painkillers
Hamilton, ON (Oct. 4, 2022) – Patients can recover from orthopedic surgery just as well without using opioid-based painkillers, says a McMaster University and Hamilton Health Sciences (HHS) study published by the Journal of the American Medical Association (JAMA).
Read Article
Transitioning JIA to Adult Care is Problematic
Juvenile idiopathic arthritis (JIA) may start in adolescence and extend into adulthood.
Read Article
Causes of Death in Lupus
The California Lupus Surveillance Project has longitudinally followed included systemic lupus erythematosus (SLE) cases and shown that overall, the leading cause of death was cardiovascular disease (CVD), followed by rheumatic disease and hematologic/oncologic conditions.
Read Article
IL-17 Switching Works in Psoriatic Disease
Analysis of data from a Czech nationwide registry of psoriatic patients receiving biologic or targeted therapies (BIOREP) has shown a high success rate when switching between specific IL-17 inhibitors.
Read Article
Great and Not So Great (9.30.2022)
This week it's the great and not-so-great on gout, chondrocalcinosis, osteoporosis and misdiagnosis. We are good at many of those things - what's not so great? Let's review the news and journal reports from the past week on RheumNow.
Read Article